J07AG01 - Haemophilus Influenzae B, Purified Antigen Conjugated |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the hemophilus influenzae B, purified antigen conjugated vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Haemophilus influenzae type b polysaccaride conjugated to tetanus carrier protein.
Therapeutic characteristics
The hemophilus influenza B vaccine is indicated for the prevention of invasive disease caused by Haemophilus influenzae type b in children from 2 months through 5 years of age. It is administered by intramuscular injections, in infants usually according to a three or four dose schedule.
Metabolism and pharmacokinetics
The hemophilus influenza B vaccine is not metabolized by the cytochrome P450 system.
References
- Government bodies
- Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
- Summary of Product Characteristics
- Norwegian medicines agency. Summary of Product Characteristics (SPC). Act-Hib. #1859
Similar drugs
© NAPOS 2024